ライフサイエンスコーパス: immunomodulator

1 apse 24 months after they stopped taking the immunomodulator).

2 growing evidence that vitamin D is a potent immunomodulator.

3 entified human anti-microbial metabolite and immunomodulator.

4 ltoheptaose was identified from WG-PS3 as an immunomodulator.

5 a previously unknown function for GP2 as an immunomodulator.

6 and is under investigation as a non-specific immunomodulator.

7 f estrogen, a well-known neuroprotectant and immunomodulator.

8 to function as both a primary adhesin and an immunomodulator.

9 ro- and anti-inflammatory properties of this immunomodulator.

10 vealing a potential function of VEGF-C as an immunomodulator.

11 as been suggested that HBeAg functions as an immunomodulator.

12 p35 heterodimer is likely to be an important immunomodulator.

13 djunct for cancer therapy, and an anti-tumor immunomodulator.

14 mes at 1 year than early monotherapy with an immunomodulator.

15 gn and their biological applications such as immunomodulators.

16 s that of a physical linkage between Ags and immunomodulators.

17 mulation from other allergens or copresented immunomodulators.

18 es (such as ATP and UTP) have emerged as key immunomodulators.

19 therapeutically delivering nucleic acids as immunomodulators.

20 plications for the use of CpG-A and CpG-B as immunomodulators.

21 could result in more effective vaccines and immunomodulators.

22 to the conserved structural features of HCMV immunomodulators.

23 tentially be developed into orally available immunomodulators.

24 the potential interference of tumor-derived immunomodulators.

25 and may have clinical utility as stand-alone immunomodulators.

26 e receiving BM185 cells expressing all three immunomodulators.

27 Lipoxins are bioactive eicosanoids that are immunomodulators.

28 iandrosterone were used together as hormonal immunomodulators.

29 ity triggered by systemic delivery of potent immunomodulators.

30 new targets for intervention, as well as new immunomodulators.

31 ancer cells and provide sustained release of immunomodulators.

32 new targets for intervention, as well as new immunomodulators.

33 atory destruction in vitro and are promising immunomodulators.

34 iculate vaccines, drug delivery systems, and immunomodulators.

35 lpha was superior to early treatment with an immunomodulator (85.3% vs 60.3% in remission; relative r

36 Therefore, development of adjuvants and immunomodulators able to enhance cell-mediated immune re

37 the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic models.

38 imply as an immunosuppressant, but as a mild immunomodulator, administration of glucosamine provides

39 nts with Crohn's disease who discontinued an immunomodulator after combination therapy found that rat

40 isease (CD) includes early administration of immunomodulators after initial treatment with corticoste

41 f curdlan, a naturally occurring beta-glucan immunomodulator, against visceral leishmaniasis, a fatal

42 ode activation, and skin sensitization using immunomodulators agonistic for a family of sphingosine-1

43 ainst divergent strains, act as adjuvants or immunomodulators, allow for sustained release of antigen

44 will enhance the potency of sunitinib as an immunomodulator and a cancer therapy.

45 al attention as both a Th1-like inflammatory immunomodulator and a pathogenic co-stimulator of autore

46 tor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheuma

47 P [c-diguanylate]) is a novel small molecule immunomodulator and immunostimulatory agent that trigger

48 Vitamin D is a strong immunomodulator and may protect against adverse pregnanc

49 orming growth factor beta1 (TGF-beta1) is an immunomodulator and potent chemotactic molecule present

50 in C57BL/6 mice since estrogen is a natural immunomodulator and we have recently reported that estro

51 these common sublethal infections may act as immunomodulators and affect population dynamics through

52 orption diseases and are also of interest as immunomodulators and anti-infectives.

53 tionally, antiepileptic maneuvers may act as immunomodulators and anti-inflammatory therapies can tre

54 Postoperative immunomodulators and antitumor necrosis factor agents ma

55 d progress to more potent treatments such as immunomodulators and biologic agents.

56 l disease (IBD) is increasingly managed with immunomodulators and biologic agents.

57 r KPro use but studies investigating various immunomodulators and biologic materials for improved ret

58 hysiology of severe asthma so more effective immunomodulators and biologic therapies can emerge.

59 Immunomodulators and biologics are now the preferred tre

60 The mainstays of treatment are immunomodulators and biologics, particularly anti-tumor

61 Parasitic helminths are potent immunomodulators and chronic infections may protect agai

62 ors (SCINs) are one important class of these immunomodulators and consist of three active members (SC

63 There have been reappraisals of immunomodulators and further evaluation of (yes, now con

64 Our data demonstrate that fungi are potent immunomodulators and have powerful effects on asthma ind

65 -infectives and both microbe- and host-based immunomodulators and their feasibility for use in asthma

66 ions and have implications for the design of immunomodulators and vaccines containing beta-glucans.

67 t approaches favor the early introduction of immunomodulators and/or antitumor necrosis factor (TNF)

68 Most patients were treated with immunomodulators and/or immunosuppressive agents, result

69 It is an immunomodulator, and studies in our laboratory have show

70 It is an immunomodulator, and studies in our laboratory have show

71 aminosalicylates, 0.5 (95% CI, 0.3-0.9) for immunomodulators, and 0.8 (95% CI, 0.6-1.1) for corticos

72 (95% CI, 0.5-1.1), 1.3 (95% CI, 0.9-1.9) for immunomodulators, and 1.0 (95% CI, 0.7-1.4) for corticos

73 utinin and neuraminidase, using adjuvants or immunomodulators, and administering IVVs by the mucosal

74 d use of medications, particularly steroids, immunomodulators, and biological agents; and a high risk

75 secrete an extensive arsenal of hemolysins, immunomodulators, and exoenzymes to cause disease.

76 Male sex, treatment with immunomodulators, and leukopenia also influenced the ris

77 ysis included sex, ethnicity, treatment with immunomodulators, and leukopenia.

78 steroids, 5-aminosalicylic acid derivatives, immunomodulators, and more recently thalidomide and pent

79 afety of long-term therapy with anti-TNF and immunomodulators, and predictors of relapse following th

80 y or autoimmune disorders), use of potential immunomodulators, and recent use of antibiotics or probi

81 tional development of novel anti-infectives, immunomodulators, and vaccines.

82 ties of mesalamine, antibiotics, budesonide, immunomodulators, anti-tumor necrosis factor alpha (anti

83 ior; beta-lactam antibiotics can function as immunomodulators, apparently through covalent binding to

84 rophylactic treatment with H. pylori-derived immunomodulators appears to be a promising strategy for

85 Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-

86 Imiquimod, another topical immunomodulator, approved for genital wart treatment in

87 Presently low-dose steroids or immunomodulators are being used but efficacy of these me

88 Immunomodulators are effective in controlling hematologi

89 ty of the NF-kappaB response to a variety of immunomodulators are mediated by core circadian protein

90 I IFNs and ICSBP, and demonstrate that these immunomodulators are required for the immunoprotective e

91 reduced myeloid-derived suppressor cells and immunomodulators ARG1, CTLA-4, IL-6, IL-10, LAG3, and PD

92 In this study, we show that the helminth immunomodulator AvCystatin, a cysteine protease inhibito

93 The 'step-up' approach includes the use of immunomodulators [azathioprine (AZA), or 6-mercaptopurin

94 Using the immunomodulator B7-DC XAb to activate cytolytic T cells

95 FTY720, a potent immunomodulator, becomes phosphorylated in vivo (FTY-P)

96 fects of in vivo administration of a soluble immunomodulator, beta-(1,6)-branched beta-(1,3)-glucan (

97 The immunomodulator Betafectin(R) PGG-glucan is a homopolyme

98 s or older with a lower use of biologics and immunomodulators but higher absolute risk of bowel surge

99 D, elderly patients used fewer biologics and immunomodulators but more systemic corticosteroids.

100 uch as interleukins, chemotherapy, and other immunomodulators, but these adjuvant treatments are ofte

101 how one molecule can serve as a double-edged immunomodulator by directing discrete biological consequ

102 r results suggested that HCV NS5A acts as an immunomodulator by inhibiting IFN-gamma production and m

103 nal domain (BET) chromatin adaptors serve as immunomodulators by directly regulating Th17 responses a

104 Immunomodulators can be divided into those that are spec

105 Blood CD14(+) monocytes are frontline immunomodulators categorized into classical, intermediat

106 mune responses by introducing genes encoding immunomodulators (CD40 ligand (CD40L), CD80, and GM-CSF)

107 ding combination therapy with a biologic and immunomodulator compared to biologic monotherapy.

108 tly since the introduction of infliximab, an immunomodulator considered particularly effective in tre

109 have revealed that osteopontin, an important immunomodulator, contributes to the increased amounts of

110 cer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of signifi

111 ibiting CD28 costimulation with the approved immunomodulator CTLA4Ig suppressed primary responses in

112 specificities, differ in sensitivity to the immunomodulator cyclosporin A.

113 uction] of immunomodulator monotherapy, 8 on immunomodulator de-escalation from combination therapy,

114 FTY720, a novel immunomodulator, displays potent immunosuppressive activ

115 FTY720 is a potent immunomodulator drug that inhibits the egress of lymphoc

116 the mycobacterial cell wall, and are potent immunomodulators during infection.

117 of medical therapy with aminosalicylates and immunomodulators during pregnancy.

118 both viruses induced a transient increase in immunomodulators, followed by viral clearance.

119 ds to be considered in evaluating IL-7 as an immunomodulator for HIV-infected patients.

120 zMPC, a novel probiotic product, is a potent immunomodulator for macrophages and may be beneficial fo

121 -tumor necrosis factor (TNF) agent and/or an immunomodulator for patients with inflammatory bowel dis

122 s clinical Phase I trial examined OKT3 as an immunomodulator for the treatment of cancer.

123 leukin-7 (IL-7) is a prospective therapeutic immunomodulator for the treatment of HIV, we evaluated t

124 ficial; here, we discovered that FTY-720, an immunomodulator for treating multiple sclerosis, can rev

125 e available in recent years, such as topical immunomodulators for atopic dermatitis, leukotriene anta

126 ory in current clinical trials using several immunomodulators for boosting antiviral immunity, immuno

127 immunity and for their development as novel immunomodulators for clinical use.

128 a single agent and in combination with other immunomodulators for inhibition of T-cell proliferation

129 e of ribavirin (alone or in combination with immunomodulators) for the treatment of respiratory syncy

130 igated the therapeutic efficacy of the novel immunomodulator FTY720 (Fingolimod), alone and in combin

131 The immunomodulator FTY720 (FTY) has been shown to be benefi

132 The novel immunomodulator FTY720 down-modulates sphingosine-1-phos

133 Administration of the immunomodulator FTY720 increased serum S1P, improved imp

134 receiving BM185 cells expressing two or more immunomodulator genes rejected challenge 50-76% of the t

135 We have reported that an immunomodulator, glucan phosphate, induces protection in

136 However, to date only a few immunomodulators have been evaluated for their efficacy

137 vents of potent treatment with biologics and immunomodulators have been recognized.

138 Cell vaccines engineered to express immunomodulators have shown feasibility in eliminating l

139 Several cytokines and immunomodulators have undergone limited study; perhaps t

140 Osteopontin (OPN) is an immunomodulator highly expressed in dystrophic muscles.

141 The data also emphasize the fact that two immunomodulators, i.e., MAN and MPL, having similar effe

142 Besides acting as an immunomodulator, IFN-alpha elicits a pleiotropic antivir

143 vel chemotherapies including epothilones and immunomodulators (IMiDs), as well as other novel agents

144 lymerase inhibitors in only 2 cases, and the immunomodulators imiquimod and thalidomide allowed 5 pat

145 i-GMP may be used clinically as an effective immunomodulator, immune enhancer, and vaccine adjuvant t

146 used clinically in humans and animals as an immunomodulator, immune enhancer, immunotherapeutic, imm

147 rial, CYT003, a Toll-like receptor-9 agonist immunomodulator, improved asthma control during inhaled

148 d some evidence exists that it may act as an immunomodulator in allograft transplantation.

149 r necrosis factor (TNF)alpha with that of an immunomodulator in attaining clinical remission and faci

150 in, acting as an innate antibiotic and as an immunomodulator in diseases such as rosacea and psoriasi

151 t complement activation serves as a critical immunomodulator in lung cancer progression, acting to dr

152 Topical ophthalmic tofacitinib may act as an immunomodulator in patients with DED.

153 yl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with mu

154 the potential therapeutic use of this novel immunomodulator in the treatment of metastatic diseases.

155 propose a novel role for a HABP as an innate immunomodulator in the treatment of MSSA and MRSA surgic

156 stigate the potential of anti-infectives and immunomodulators in asthma.

157 DNAs) are currently being evaluated as novel immunomodulators in clinical trials.

158 have been studied for their potential use as immunomodulators in disease.

159 gh phosphocholine oligosaccharides are known immunomodulators in human nematode and trematode infecti

160 or dose reduction) of anti-TNF agents and/or immunomodulators in patients in remission from IBD.

161 go-related gene (ERG) potassium channels and immunomodulators in the control of rest and locomotor ac

162 t arachidonic acid metabolites, which act as immunomodulators in the immune response to dietary antig

163 (LM) and lipoarabinomannan (LAM), are potent immunomodulators in tuberculosis and leprosy.

164 ave been raised regarding the use of topical immunomodulators in young children with atopic dermatiti

165 imum tolerated dose of lenalidomide, an oral immunomodulator, in Japanese patients with relapsed adul

166 Opiates are known to function as immunomodulators, in part by effects on T cells.

167 Clinical data using other immunomodulators, including 6-thioguanine, mycophenolate

168 Histamine is an important immunomodulator involved in allergic reactions and infla

169 choosing to stop either the anti-TNF or the immunomodulator is a case-by-case decision based on the

170 The role of melatonin as an immunomodulator is well established.

171 The importance of these immunomodulators is highlighted by the number of immune

172 her investigate the potential of OKT4A as an immunomodulator, it was necessary to decrease its immuno

173 onstrate that the oral administration of the immunomodulator JBT 3002 combined with i.p. injection of

174 ect of irinotecan (CPT-11) combined with the immunomodulator JBT 3002, a synthetic bacterial lipopept

175 at transcriptional regulation of a subset of immunomodulators, known as the staphylococcal superantig

176 ory Takayasu arteritis have responded to the immunomodulator leflunomide.

177 include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kina

178 mised their ability to induce NOD2-dependent immunomodulators like cyclooxygenase (COX)-2, suppressor

179 lobenzaprine; the analgesic nefopam; and the immunomodulator lobenzarit.

180 suggest that the use of costimulation-based immunomodulators may have significant repercussions on t

181 RSV disease and evidence that noninfectious immunomodulators may impact pathogen-specific immunity.

182 ests that high levels of vitamin D, a potent immunomodulator, may decrease the risk of multiple scler

183 ity Index (CCI), radiation and chemotherapy, immunomodulator medications, albumin, preoperative diagn

184 ctadecylammonium liposomes incorporating two immunomodulators (monomycolyl glycerol analog and polyin

185 antibiotics (RR, 0.41; 95% CrI, 0.15-0.92), immunomodulator monotherapy (RR, 0.33; 95% CrI, 0.13-0.6

186 antibiotics (RR, 0.26; 95% CrI, 0.08-0.61), immunomodulator monotherapy (RR, 0.36; 95% CrI, 0.17-0.6

187 Stopping immunomodulator monotherapy after a period of remission

188 lation [drug cessation or dose reduction] of immunomodulator monotherapy, 8 on immunomodulator de-esc

189 been used to promote the delivery of a model immunomodulator, mycophenolic acid (MPA), to the lymphat

190 erity (CDEIS) from the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC

191 rom its role (i) as an immunogen, (ii) as an immunomodulator of host anti-inflammatory activities, or

192 We theorized that OMP P6 is a potent immunomodulator of human macrophages.

193 ing the possibility to use sGARP as a potent immunomodulator of inflammatory diseases including trans

194 st report to show the potential of VIP as an immunomodulator of Pg-stimulated inflammatory pathways i

195 hrough this mechanism, NO may function as an immunomodulator of the vessel wall and thus mediate infl

196 Since the role of PGs as immunomodulators of human cerebral malaria (CM) has not

197 tructure and function is required to develop immunomodulators of IL-5-mediated inflammatory responses

198 n be broadly applied to other small-molecule immunomodulators of interest for vaccines and immunother

199 athogenesis and high-throughput screening of immunomodulators of phagocytosis.

200 n) with anti-CD3 antibody (a T cell-directed immunomodulator) offers better protection than either en

201 e examined the effects of PGE2, a well-known immunomodulator, on the production of IL-23 by bone marr

202 ednisone at baseline, and no previous use of immunomodulators or biologics.

203 ated with early anti-TNFalpha therapy, early immunomodulator, or no early immunotherapy.

204 enable delivery of imaging contrast agents, immunomodulators, or chemotherapy agents in adoptive cel

205 our necrosis factor alpha (TNFalpha) agents, immunomodulators, or colectomy among those initially tre

206 interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreductive treatment).

207 ts, such as calcineurin inhibitors and other immunomodulators, or novel anti-inflammatory treatments,

208 monoclonal antibodies, virulence disruptors, immunomodulators, phage therapies, microbiome-based ther

209 xamine the potency of two beta-chemokines as immunomodulators, plasmid DNA encoding beta-chemokines C

210 Sunitinib is also an immunomodulator, potently reversing myeloid-derived supp

211 Therefore, anti-CD154 as the sole immunomodulator prevented the recurrence of diabetes in

212 Treatment with the three immunomodulators prevented or delayed mortality and weig

213 rotein A (SP-A), an oxidant-sensitive T cell immunomodulator produced by alveolar type II cells.

214 te dysregulation occurs through the negative immunomodulators programmed death-1 (PD-1) and suppresso

215 rgone a considerable and unique expansion of immunomodulator proteins, some of which we highlight as

216 pha, and downregulation of NF-kappa B by the immunomodulator pyrrolidinedithiocarbamate enhanced the

217 rotein or peptide antigens and a tolerogenic immunomodulator, rapamycin, to induce durable and antige

218 remained superior to early treatment with an immunomodulator (relative risk, 1.51; 95% CI, 1.20-1.89;

219 Consistent with this, ES-62, an immunomodulator secreted by the parasitic worm Acanthoch

220 design could be adapted to drive additional immunomodulators, sense other cancers, and potentially t

221 H. pylori or treated with H. pylori-derived immunomodulators showed reduced anaphylaxis upon allerge

222 vaccination against a secreted tick salivary immunomodulator, sialostatin L2, can lead to decreased f

223 In the immunomodulator study, mice were treated with glucan pho

224 Immunomodulators such as Bacillus Calmette-Guerin and in

225 There is evidence that conventional immunomodulators such as mycophenolate mofetil and biolo

226 Immunomodulators such as SP-D and ST2 also contribute.

227 ammatory cell death that can be leveraged by immunomodulators such as the danger signal calreticulin.

228 Addition of immunomodulators such as thiopurines or possibly methotr

229 on of inflammatory cytokines and noncytokine immunomodulators, such as PGE2, during differentiation a

230 The topical immunomodulators tacrolimus and pimecrolimus have been e

231 treatment of skin disease, using the topical immunomodulators tacrolimus, pimecrolimus, and imiquimod

232 ccurring glucosaminoglycan and a pleiotropic immunomodulator that binds to a variety of proteins.

233 t shutoff (vhs) protein is a multifunctional immunomodulator that counteracts the innate immune respo

234 We propose LJM11 as an immunomodulator that drives an efficient and controlled

235 Adenosine is an endogenous immunomodulator that has been shown to exhibit anti-infl

236 TLR4 protein levels in mice treated with an immunomodulator that increases survival in polymicrobial

237 data indicate that HVS14 can function as an immunomodulator that may contribute to the immunopatholo

238 hmania-derived trimannose represents a novel immunomodulator that provides early type 1-skewed cytoki

239 sgammac expression is a naturally occurring immunomodulator that regulates gammac cytokine signaling

240 ivation, attention has focused on the use of immunomodulators that affect T cell responses.

241 hosphate dehydrogenase inhibitors, and other immunomodulators that are being evaluated as adjunctive

242 Mycobacterial lipids are potent immunomodulators that contribute to the granulomatous re

243 Studies on emerging immunomodulators that dampen autoreactivity without affe

244 erefore can be added to the list of cytokine immunomodulators that might be beneficial in the treatme

245 trated that the anthrax toxins are important immunomodulators that promote immune evasion of the bact

246 resents a new class of vaccine adjuvants and immunomodulators that stimulate NKT cells to secrete Th1

247 Among the immunomodulators, the T-cell antigen MART-1 and the prot

248 Newer nucleoside analogues and other immunomodulator therapies are being investigated.

249 Co-administration of immunomodulator therapy and adalimumab was associated wi

250 antiviral therapy and of combined antiviral-immunomodulator therapy for influenza.

251 Immunomodulator therapy is effective for patients with C

252 l [CI], 1.14-1.75; P = .0017), whereas early immunomodulator therapy was no different than no early i

253 95% CI, 1.20-1.89; P = .0004), whereas early immunomodulator therapy was no different than no early i

254 y associated with combination adalimumab and immunomodulator therapy with that of adalimumab monother

255 disease, by history of surgical resection or immunomodulator therapy, and with disease diagnosed befo

256 use of corticosteroids, laser, surgery, and immunomodulator therapy.

257 een aimed at advancing anti-inflammatory and immunomodulator therapy.

258 ly, glycine has been shown to be a potential immunomodulator; therefore, the purpose of this study wa

259 al strategy is the use of chemotherapy as an immunomodulator to enhance the effect of cancer vaccines

260 during fungal infection, where it acts as an immunomodulator to promote fungal clearance and to regul

261 The addition of immunomodulators to anti-TNF therapies can optimize thei

262 mia cells with lentiviral vectors to express immunomodulators to elicit antileukemic immune responses

263 cy and pluripotency evolved in tick salivary immunomodulators to evade immune recognition by the host

264 Switching from injectable immunomodulators to fingolimod is associated with fewer

265 n secrete high levels of cytokines and other immunomodulators to mediate host defense and tissue infl

266 pical and systemic corticosteroids, systemic immunomodulators, topical and systemic retinoids, and la

267 Immunomodulator treatments, including the recently popul

268 , while a mosquito bite alone induced strong immunomodulators (tumor necrosis factor alpha [TNF-alpha

269 witching therapy to fingolimod or injectable immunomodulators up to 12 months after on-treatment clin

270 associated with long-term corticosteroid and immunomodulator use if topical medication is not suffici

271 with ulcerative colitis supported continued immunomodulator use.

272 e and pomalidomide are members of a class of immunomodulators used as anticancer agents.

273 . pylori components (bacterial lysate or the immunomodulator VacA) and subsequently subjected them to

274 Here we report the development of new immunomodulators via control of shape transition among R

275 human immunodeficiency virus type 1 (HIV-1) immunomodulator VPU, reduced steady-state levels of bone

276 A concurrent immunomodulator was required.

277 ermal PAF-R to induce the synthesis of these immunomodulators was tested using a model system created

278 el host cell proteins downregulated by viral immunomodulators, we previously observed that K5, as wel

279 hage population induced by a single parasite immunomodulator, which protects against mucosal inflamma

280 oactive intestinal peptide (VIP) is a potent immunomodulator, whose role in PDC function is unknown.

281 t an improved understanding of virus-encoded immunomodulators will enhance our ability to design reag

282 diseases, establishing CD45 as an important immunomodulator with a significant influence on disease

283 FTY720 is a novel immunomodulator with a unique mechanism of action, i.e.

284 monotherapy (RR, 0.36; 95% CrI, 0.17-0.63), immunomodulator with antibiotics (RR, 0.11; 95% CrI, 0.0

285 monotherapy (RR, 0.33; 95% CrI, 0.13-0.68), immunomodulator with antibiotics (RR, 0.16; 95% CrI, 0.0

286 Transforming growth factor beta is a potent immunomodulator with both pro- and antiinflammatory acti

287 Methotrexate is an immunomodulator with effects on helper T-cell signaling

288 how for the first time that AICAR is a novel immunomodulator with promising beneficial effects for th

289 Some fatty acids (FAs) are potent immunomodulators with virucidal activity, and their prim

290 Use of anti-TNF agents, corticosteroids, and immunomodulators within 90 days of surgery was identifie